Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Bargagli

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Clinical Journal of the American Society of Nephrology : CJASN|June 13, 2020
Urinary Lithogenic Risk Profile in ADPKD Patients Treated with TolvaptanMatteo Bargagli, Nasser A Dhayat, Manuel Anderegg, et al.
Journal of Nephrology|December 17, 2022
The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney diseasePietro Manuel Ferraro, Matteo Bargagli, Nicolas Faller, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|March 16, 2023
Determinants of renal papillary appearance in kidney stone formers: An in-depth examinationMatteo Bargagli, Francesco Pinto, Rossella De Leonardis, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 29, 2022
Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patientsMatteo Bargagli, Andri Vetsch, Manuel A Anderegg, et al.
Nature Medicine|January 3, 2025
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trialManuel A Anderegg, Simeon Schietzel, Matteo Bargagli, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 28, 2024
Prevalence and characteristics of genetic disease in adult kidney stone formersManuel A Anderegg, Eric G Olinger, Matteo Bargagli, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 30, 2023
Urinary lithogenic profile of patients with non-alcoholic fatty liver diseaseMatteo Bargagli, Antonio Liguori, Cecilia Napodano, et al.
Kidney International Reports|May 20, 2024
The Vitamin D Metabolite Diagnostic Ratio Associates With Phenotypic Traits of Idiopathic HypercalciuriaNasser A Dhayat, Cédric Mattmann, Harald Seeger, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 10, 2025
Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney Stones: Post Hoc Analysis of the NOSTONE TrialAndreas Christe, Elias Primetis, Grazia M Cereghetti, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Journal of the American Society of Nephrology : CJASN|June 13, 2020
Urinary Lithogenic Risk Profile in ADPKD Patients Treated with TolvaptanMatteo Bargagli, Nasser A Dhayat, Manuel Anderegg, et al.
Journal of Nephrology|December 17, 2022
The role of urinary supersaturations for lithogenic salts in the progression of autosomal dominant polycystic kidney diseasePietro Manuel Ferraro, Matteo Bargagli, Nicolas Faller, et al.
Archivio Italiano Di Urologia, Andrologia : Organo Ufficiale [Di] Societa Italiana Di Ecografia Urologica E Nefrologica|March 16, 2023
Determinants of renal papillary appearance in kidney stone formers: An in-depth examinationMatteo Bargagli, Francesco Pinto, Rossella De Leonardis, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 29, 2022
Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patientsMatteo Bargagli, Andri Vetsch, Manuel A Anderegg, et al.
Nature Medicine|January 3, 2025
Empagliflozin in nondiabetic individuals with calcium and uric acid kidney stones: a randomized phase 2 trialManuel A Anderegg, Simeon Schietzel, Matteo Bargagli, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|March 28, 2024
Prevalence and characteristics of genetic disease in adult kidney stone formersManuel A Anderegg, Eric G Olinger, Matteo Bargagli, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|May 30, 2023
Urinary lithogenic profile of patients with non-alcoholic fatty liver diseaseMatteo Bargagli, Antonio Liguori, Cecilia Napodano, et al.
Kidney International Reports|May 20, 2024
The Vitamin D Metabolite Diagnostic Ratio Associates With Phenotypic Traits of Idiopathic HypercalciuriaNasser A Dhayat, Cédric Mattmann, Harald Seeger, et al.
Clinical Journal of the American Society of Nephrology : CJASN|March 10, 2025
Hydrochlorothiazide and Bone Mineral Density in Patients with Kidney Stones: Post Hoc Analysis of the NOSTONE TrialAndreas Christe, Elias Primetis, Grazia M Cereghetti, et al.
Pageof 3